Patent: 8,168,593
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 8,168,593
Title: | Mutated netrin-4, fragments thereof and their use as medicines |
Abstract: | A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies. |
Inventor(s): | Plouet; Jean (Paris, FR), Alemany; Monica (Paris, FR) |
Assignee: | Centre National de la Recherche Scientifique (Paris, FR) IVS Institut des Vaisseaux et du Sang (Paris, FR) |
Application Number: | 13/171,756 |
Patent Claims: | see list of patent claims |
Details for Patent 8,168,593
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2024-11-22 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2024-11-22 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2024-11-22 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2024-11-22 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2024-11-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |